Gilead's Yescarta Wins FDA Label Update, Expands Patient Eligibility

Gilead's Kite unit has received a favorable label update from the US FDA for its CAR-T therapy Yescarta, allowing its use in a subset of patients with a rare form of lymphoma. The update removes a previous limitation on the treatment's use, expanding its potential patient pool.